References
- Rilutek S.P.Cs [updated April 14, 2016[ Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000109/human_med_001039.jsp&mid=WC0b01ac058001d124Accessed January 11, 2017
- Riluzole Zentiva [webpage on the Internet]LondonEuropen Medicines Agency2012 [updated May 30, 2018] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002622/human_med_001551.jsp&mid=WC0b01ac058001d124Accessed January 11, 2017
- BensimonGLacomblezLMeiningerVA controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study GroupN Engl J Med199433095855918302340
- BritesDVazARMicroglia centered pathogenesis in ALS: insights in cell interconnectivityFront Cell Neurosci2014811724904276
- RomanoSCoarelliGMarcotulliCRiluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trialLancet Neurol2015141098599126321318
- MillerRGMitchellJDMooreDHRiluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Cochrane Database Syst Rev20123CD001447
- IBM Micromedex® Web Applications Access [webpage on the Internet]Armonk, NYIBM Corporation2018 Available from: http://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch#Accessed January 11, 2017
- Committee for Medicinal Product for Human UseGuideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/12/WC500199241.pdfAccessed April 18, 2018
- MathisSCouratierPJulianACorciaPLe MassonGCurrent view and perspectives in amyotrophic lateral sclerosisNeural Regen Res201712218118428400790
- de CarvalhoMDo We Have a Channel Solution for ALS?EBioMedicine20152121842184326844251
- PetrovDMansfieldCMoussyAHermineOALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Front Aging Neurosci201796828382000
- Radicava S.P.Cs [updated May, 2017] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209176lbl.pdfAccessed April 18, 2018
- ChenLLiuXTangLZhangNFanDLong-Term Use of Riluzole Could Improve the Prognosis of Sporadic Amyotrophic Lateral Sclerosis Patients: A Real-World Cohort Study in ChinaFront Aging Neurosci2016824627822184
- SabatéEAdherence to Long-Term Therapies: Evidence for ActionGenevaWorld Health Organization2003
- OnestiESchettinoIGoriMCDysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole ManagementFront Neurol2017897696428293215
- DyerAMSmithARiluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosisDrug Des Devel Ther2017115964
- TurnerMRHardimanOBenatarMControversies and priorities in amyotrophic lateral sclerosisLancet Neurol201312331032223415570